Multiple BM-MSCs (Lenzumestrocel) treatment in patients with amyotrophic lateral sclerosis: Rationale and design of phase III clinical (ALSUMMIT) trial.
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 오기욱 | - |
dc.date.accessioned | 2021-07-30T08:21:17Z | - |
dc.date.available | 2021-07-30T08:21:17Z | - |
dc.date.created | 2021-07-01 | - |
dc.date.issued | 2020-12-05 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/6477 | - |
dc.publisher | MND association | - |
dc.title | Multiple BM-MSCs (Lenzumestrocel) treatment in patients with amyotrophic lateral sclerosis: Rationale and design of phase III clinical (ALSUMMIT) trial. | - |
dc.type | Conference | - |
dc.contributor.affiliatedAuthor | 오기욱 | - |
dc.identifier.bibliographicCitation | 31st International Symposium on ALS/MND | - |
dc.relation.isPartOf | 31st International Symposium on ALS/MND | - |
dc.citation.title | 31st International Symposium on ALS/MND | - |
dc.citation.conferencePlace | 온라인 | - |
dc.type.rims | CONF | - |
dc.description.journalClass | 1 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.